Epclusa 400mg/100mg It combines sofosbuvir and velpatasvir. It is more than 90% effective for hepatitis C genotypes one through six.
Sofosbuvir/velpatasvir, sold under the brand name Epclusa among others, is a fixed dose combination medication for the treatment of hepatitis C. It combines sofosbuvir and velpatasvir. It is more than 90% effective for hepatitis C genotypes one through six. It also works for hepatitis C in those who also have cirrhosis or HIV/AIDS. It is taken by mouth.
The combination is generally well tolerated. Common side effects include headaches, feeling tired, trouble sleeping, and nausea. It has not been studied in pregnant women or during breastfeeding. Greater care is required in those who are also infected with hepatitis B. Sofosbuvir works by blocking the NS5B protein and velpatasvir works by blocking the NS5A protein.
Sofosbuvir/velpatavir was approved for medical use in the United States in 2016. It is on the World Health Organization’s List of Essential Medicines, the most effective and safe medicines needed in a health system. As of 2017, in the United States a course of treatment costs about 74,800 USD while in the developing world it costs about 900 USD.